IP Library Granted Patent US 7,790,397
Granted Patent B2
US 7,790,397 · App. 10/437,651 · Granted Sep 7, 2010

Making a prognosis in cases of cardiac disease using a combination of markers

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,790,397
App. No.
10/437,651
Granted
Sep 7, 2010
Kind
B2
Abstract

The present invention concerns methods for diagnosing myocardial infarction, for performing risk stratification of myocardial infarction, for making a prognosis of a disease course in a myocardial infarction patient, for identifying a patient with elevated risk of myocardial infarction, or combinations thereof, wherein a determination of at least three markers is performed on a patient sample. Furthermore, kits for performing the methods are provided.

Claims (8)

1. A method for making a short-term prognosis up to 30 days for a myocardial infarction patient by determining the level of three markers from a sample from the patient, wherein the three markers consist of N-terminal fragment of pro-BNP (NT-ProBNP) marker, at least one ischemic marker selected from the group consisting of troponin T and troponin I, and at least one inflammatory marker selected from the group consisting of C-reactive protein (CRP) and IL-6, comparing the pro-BNP (NT-ProBNP) level, the level of at least one of the ischemic markers and at least one of the inflammatory markers to a control, wherein an elevation of each the pro-BNP (NT-ProBNP), at least one of the ischemic markers, and at least one of the inflammatory markers as compared to the control indicates a less favorable prognosis.

2. The method according to claim 1 , wherein the level of the markers are determined in parallel.

3. The method according to claim 1 , wherein a single patient sample is used.

4. The method according to claim 1 , wherein the presence, quantity, or both presence and quantity of said markers is determined on an automated analyzer.

5. The method according to claim 1 , wherein the presence, quantity, or both presence and quantity of said markers is determined using an enzyme immunoassay, an electrochemiluminescence immunoassay, an immunoassay, or a turbidimetric test.

6. The method of claim 1 , wherein the short-term prognosis is for the course of 72 hours.

7. The method of claim 1 , wherein the short-term prognosis is for the course of 5 days.

8. The method of claim 1 , wherein the short-term prognosis is for the course of 10 days.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2010
From: HAMM, CHRISTIAN
To: ROCHE DIAGNOSTICS GMBH
Reel/Frame 024636/0153 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2010
From: SPANUTH, EBERHARD
To: ROCHE DIAGNOSTICS GMBH
Reel/Frame 024636/0172 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2010
From: ROCHE DIAGNOSTICS GMBH
To: ROCHE DIAGNOSTICS CORPORATION
Reel/Frame 024636/0181 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2004
From: ROCHE DIAGNOSTICS CORPORATION
To: ROCHE DIAGNOSTICS OPERATIONS, INC.
Reel/Frame 015215/0061 →